HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christopher D M Fletcher Selected Research

Myoepithelioma

10/2019Cutaneous Syncytial Myoepithelioma Is Characterized by Recurrent EWSR1-PBX3 Fusions.
7/2015ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.
1/2004Cutaneous myoepithelioma: a clinicopathologic and immunohistochemical study of 14 cases.
9/2003Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christopher D M Fletcher Research Topics

Disease

107Neoplasms (Cancer)
10/2022 - 01/2002
22Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
03/2013 - 02/2002
19Sarcoma (Soft Tissue Sarcoma)
01/2022 - 03/2002
8Carcinoma (Carcinomatosis)
01/2018 - 03/2002
5Neurofibrosarcoma (MPNST)
10/2020 - 01/2010
5Melanoma (Melanoma, Malignant)
01/2019 - 03/2002
4Fibrosarcoma
01/2021 - 05/2011
4Carcinogenesis
01/2021 - 05/2004
4Myoepithelioma
10/2019 - 09/2003
4Liposarcoma
02/2017 - 02/2005
4Benign Fibrous Histiocytoma (Dermatofibroma)
09/2015 - 01/2002
3Breast Neoplasms (Breast Cancer)
01/2019 - 01/2007
3Hemangiosarcoma (Angiosarcoma)
01/2019 - 08/2005
3Perivascular Epithelioid Cell Neoplasms
02/2018 - 09/2009
3Necrosis
01/2018 - 10/2008
3Genetic Translocation (Chromosomal Translocation)
10/2015 - 12/2002
3Fasciitis (Fascitis)
10/2008 - 06/2002
2Fibrosis (Cirrhosis)
01/2021 - 02/2004
2Hemangioendothelioma
12/2020 - 05/2017
2Vascular Neoplasms (Neoplasms, Vascular)
12/2020 - 05/2017
2Angiomyolipoma
02/2018 - 09/2009
2Neoplasm Metastasis (Metastasis)
01/2018 - 11/2014
2Myopericytoma
08/2017 - 06/2017
2Synovial Sarcoma (Synovioma)
06/2017 - 10/2016
2Hemangiopericytoma
06/2017 - 05/2011
2Neurofibroma
01/2017 - 01/2010
2Ewing Sarcoma (Sarcoma, Ewing)
04/2016 - 08/2014
2Disease Progression
01/2016 - 09/2009
2Neurilemmoma (Schwannoma)
05/2015 - 09/2007
2Angiofibroma
05/2012 - 05/2010
2Tuberous Sclerosis (Bourneville's Disease)
02/2010 - 09/2009
2Leukemia
11/2008 - 06/2003
2Nerve Sheath Neoplasms (Nerve Sheath Neoplasm)
09/2007 - 07/2005
1Rhabdomyoma
12/2022
1Malignant Mesothelioma
07/2022
1Leiomyosarcoma
01/2022
1Solitary Fibrous Tumors
07/2021

Drug/Important Bio-Agent (IBA)

20Imatinib Mesylate (Gleevec)FDA Link
03/2013 - 02/2002
19DesminIBA
01/2022 - 11/2004
18S100 Proteins (S 100 Protein)IBA
01/2021 - 11/2004
17Biological ProductsIBA
01/2021 - 03/2002
16Keratins (Keratin)IBA
10/2019 - 01/2004
16Proteins (Proteins, Gene)FDA Link
01/2019 - 04/2002
13Mucin-1 (CA 15-3 Antigen)IBA
01/2022 - 01/2002
12Phosphotransferases (Kinase)IBA
10/2020 - 01/2003
11RNA (Ribonucleic Acid)IBA
12/2022 - 03/2005
11CollagenIBA
12/2018 - 01/2002
8DNA (Deoxyribonucleic Acid)IBA
12/2022 - 07/2004
8Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2008 - 04/2002
7Calmodulin-Binding Proteins (Caldesmon)IBA
10/2022 - 07/2005
7ChromatinIBA
10/2022 - 09/2003
4Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2021 - 06/2003
4Messenger RNA (mRNA)IBA
10/2016 - 10/2004
4ParaffinIBA
01/2016 - 07/2004
4Neurofilament ProteinsIBA
10/2009 - 07/2005
3SynaptophysinIBA
10/2022 - 01/2006
3CAM 5.2 antigenIBA
01/2022 - 12/2007
3CateninsIBA
01/2022 - 06/2017
3Transcription Factors (Transcription Factor)IBA
01/2021 - 10/2015
3MART-1 AntigenIBA
02/2018 - 04/2008
3Microphthalmia-Associated Transcription FactorIBA
02/2018 - 04/2008
3Capsules (Microcapsules)IBA
08/2017 - 09/2007
3Formaldehyde (Formol)FDA Link
01/2016 - 07/2013
3Monoclonal AntibodiesIBA
07/2015 - 03/2009
3Phosphopyruvate Hydratase (Enolase)IBA
01/2014 - 01/2006
3beta CateninIBA
07/2013 - 02/2006
3Oncogene Proteins (Oncogene Protein)IBA
03/2013 - 01/2003
3Sunitinib (Sutent)FDA Link
02/2010 - 11/2008
3Claudin-1IBA
10/2009 - 07/2005
3Tyrosine Kinase InhibitorsIBA
03/2009 - 08/2002
3Glial Fibrillary Acidic ProteinIBA
07/2008 - 07/2005
2Biomarkers (Surrogate Marker)IBA
07/2022 - 02/2018
2ChromograninsIBA
01/2022 - 01/2006
2Sirolimus (Rapamycin)FDA Link
01/2018 - 02/2010
2Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
08/2017 - 07/2015
2MicroRNAs (MicroRNA)IBA
10/2016 - 01/2010
2LigandsIBA
04/2016 - 07/2013
2AntibodiesIBA
09/2015 - 07/2013
2Protein Isoforms (Isoforms)IBA
06/2014 - 12/2003
2Platelet-Derived Growth FactorIBA
06/2011 - 10/2006
2Complementary DNA (cDNA)IBA
12/2010 - 09/2002
2Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
11/2008 - 12/2003
2HemosiderinIBA
02/2006 - 02/2004
2RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
03/2005 - 07/2004
1Cadherins (E-Cadherin)IBA
01/2022
1Myosin Heavy Chains (Myosin Heavy Chain)IBA
01/2022
1MyogeninIBA
01/2022
1NFI Transcription FactorsIBA
07/2021
1STAT6 Transcription FactorIBA
07/2021
1c-Mer Tyrosine KinaseIBA
01/2021
1Polytetrafluoroethylene (Teflon)FDA Link
01/2021
1Pharmaceutical PreparationsIBA
01/2021
12-(N-cyclohexylamino)ethanesulfonic acid (CHES)IBA
12/2020
1tyrosine receptor (receptor, tyrosine)IBA
10/2020
1Cyclin D1IBA
01/2020

Therapy/Procedure

17Therapeutics
01/2021 - 04/2002
6Drug Therapy (Chemotherapy)
01/2018 - 06/2002
3Aftercare (After-Treatment)
01/2019 - 05/2006
3Radiotherapy
01/2017 - 08/2005
1Neoadjuvant Therapy
01/2021